TriangleMosunetuzumab (NCT04792502)
Mosunetuzumab trial for Follicular Lymphoma (NCT04792502). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with previously untreated CD20-positive follicular or marginal zone lymphoma that needs systemic treatment. Grade 3b follicular lymphoma and transformed lymphoma are excluded.
The idea: mosunetuzumab links CD20-positive cells to T cells. Patients start four 21-day cycles of injections under the skin. Complete responders continue mosunetuzumab alone; partial responders add daily oral lenalidomide for cycles five through eight. Patients still in partial response can receive four more cycles.
This phase 2 study plans 52 patients. Adam Olszewski leads at Brown; two US sites recruit in Providence and New Brunswick.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.